WHO Sounds Warning Over Severe Lack of Weight-Loss Injections

Under one in 10 individuals who could benefit from obesity jabs like Wegovy are able to get them, caution the global health agency as it releases its first recommendations on the medications.

With in excess of 1,000,000,000 people worldwide currently classified as obese, it is advocating for increased and just access to these injectable treatments.

Per projections, more than two billion are projected to be living with obesity by 2030 unless action is taken.

"Our latest guidance acknowledges that obesity is a long-term condition that can be treated with comprehensive and lifelong treatment," said WHO director-general Tedros Adhanom Ghebreyesus.

Substantial prices, constrained manufacturing, and supply-chain constraints are major hurdles to universal availability to the jabs that can assist patients in reducing significant body mass, explains the body.

Skinny Jab Shortage

Despite the current most favorable case, the supply of such drugs could only cover about 100 million people – less than 10% of those who need them, as stated by the WHO.

The guideline calls on nations and manufacturers to widen availability, through approaches including voluntary licensing.

A patent on semaglutide – the primary ingredient of a leading brand – is scheduled to end in multiple countries in 2026.

The Way Weight-Loss Drugs Function

The injections imitate a biological compound to slow digestion, curb appetite and boost satiety so individuals consume fewer calories.

Patients usually see weight reduction in the initial weeks of commencing the regular doses.

Evidence indicates users may see weight return within a year of stopping the drug, as their normal food cravings return.

To be above a healthy weight elevates your risk for contracting medical conditions, such as diabetes, heart disease, stroke, and certain cancers.

Obesity impacts people in countries worldwide and was linked to millions of fatalities worldwide in 2024, as per the health agency.